CL2011001177A1 - Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon. - Google Patents

Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon.

Info

Publication number
CL2011001177A1
CL2011001177A1 CL2011001177A CL2011001177A CL2011001177A1 CL 2011001177 A1 CL2011001177 A1 CL 2011001177A1 CL 2011001177 A CL2011001177 A CL 2011001177A CL 2011001177 A CL2011001177 A CL 2011001177A CL 2011001177 A1 CL2011001177 A1 CL 2011001177A1
Authority
CL
Chile
Prior art keywords
ceftiofur
propylene glycol
wetting agent
benzyl alcohol
cottonseed oil
Prior art date
Application number
CL2011001177A
Other languages
English (en)
Inventor
Majid Johnson Alan Awasthi Atul Goswami Jitendra Razzak
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41682851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Inc filed Critical Merial Inc
Publication of CL2011001177A1 publication Critical patent/CL2011001177A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación veterinaria o farmacéuticamente aceptable que comprende una suspención inyectable de ceftiofur y por lo menos un agente floculante o mejorador de capacidad de resuspensión; método para mejorar la capacidad de resuspensión de una suspensión; método para prevenir o tratar un desorden o enfermedad respiratoria en un animal.
CL2011001177A 2008-11-19 2011-05-19 Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon. CL2011001177A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11603108P 2008-11-19 2008-11-19
US11976408P 2008-12-04 2008-12-04

Publications (1)

Publication Number Publication Date
CL2011001177A1 true CL2011001177A1 (es) 2011-09-16

Family

ID=41682851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001177A CL2011001177A1 (es) 2008-11-19 2011-05-19 Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon.

Country Status (15)

Country Link
US (1) US20100125060A1 (es)
EP (1) EP2367572B1 (es)
JP (1) JP5685193B2 (es)
KR (1) KR101748890B1 (es)
CN (1) CN102341125B (es)
AU (1) AU2009316708B2 (es)
BR (1) BRPI0922041A8 (es)
CA (1) CA2743551C (es)
CL (1) CL2011001177A1 (es)
CO (1) CO6390043A2 (es)
ES (1) ES2693700T3 (es)
MX (1) MX2011005217A (es)
NZ (1) NZ592984A (es)
WO (1) WO2010059717A2 (es)
ZA (1) ZA201103479B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2849723B1 (en) * 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
AR091784A1 (es) * 2012-07-17 2015-02-25 Bayer New Zealand Ltd Formaciones inyectables de antibiotico y sus metodos de aplicacion
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
PL3082762T3 (pl) 2013-12-16 2022-02-14 Zoetis Services Llc Kompozycje ketoprofenowe o długim działaniu
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
CN107049943B (zh) * 2017-05-10 2020-02-14 郑州百瑞动物药业有限公司 奶牛用盐酸头孢噻呋注射液及其制备方法
CA3132159C (en) * 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin
CN117530920B (zh) * 2023-12-08 2025-09-23 艾美科健（中国）生物医药有限公司 一种头孢噻呋复方注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1181672B (it) * 1984-10-25 1987-09-30 Upjohn Co Cefalosporina alogenidrato cristallino
WO1989004313A1 (en) * 1987-11-10 1989-05-18 The Upjohn Company Cephalosporin antibiotics
KR100296810B1 (ko) * 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
JP2004504357A (ja) * 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
MXPA03002056A (es) * 2000-09-12 2003-07-24 Pharmacia & Upjohn Company Composicion farmaceutica con actividad de agua especifica.
MXPA03002055A (es) * 2000-09-12 2004-12-13 Upjohn Co Composicion farmaceutica con excipiente modificado.
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
CN100534433C (zh) * 2005-12-12 2009-09-02 浙江升华拜克生物股份有限公司 一种含头孢噻呋的兽用粉针注射剂

Also Published As

Publication number Publication date
KR20110092312A (ko) 2011-08-17
NZ592984A (en) 2012-12-21
AU2009316708B2 (en) 2014-07-17
MX2011005217A (es) 2011-06-01
CA2743551A1 (en) 2010-05-27
ES2693700T3 (es) 2018-12-13
KR101748890B1 (ko) 2017-06-19
JP2012509337A (ja) 2012-04-19
CN102341125B (zh) 2014-02-12
CN102341125A (zh) 2012-02-01
CO6390043A2 (es) 2012-02-29
US20100125060A1 (en) 2010-05-20
CA2743551C (en) 2017-08-15
JP5685193B2 (ja) 2015-03-18
EP2367572A2 (en) 2011-09-28
WO2010059717A2 (en) 2010-05-27
BRPI0922041A2 (pt) 2015-12-22
EP2367572B1 (en) 2018-08-29
WO2010059717A3 (en) 2011-09-09
ZA201103479B (en) 2012-02-29
AU2009316708A1 (en) 2010-05-27
BRPI0922041A8 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
CL2011001177A1 (es) Formulacion inyectable que comprende ceftiofur, alcohol bencilico, propilenglicol, un agente humectante y aceite de semilla de algodon.
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
CL2012000269A1 (es) Formulacion farmaceutica inyectable subcutanea altamente concentrada de un anticuerpo anti-her2 que comprende dicho anticuerpo, un amortiguador, un estabilizador, un tensioactivo no ionico y una enzima hialuronidasa; dispositivo de inyeccion; kit y uso de la formulacion para tratar enfermedades tales como cancer.
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2008000058A1 (es) Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
AR080721A1 (es) 1-((3-ciano-piridin-2-il) metil]-3-metil-7-(2-butin-1-il)-8- (3-(r)- amino-piperidin-1-il)- xantina para tratamiento de un trastorno metabolico de un animal no humano predominantemente carnivoro
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2009000625A1 (es) Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo.
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
CL2011000423A1 (es) Composicion que comprende un compuesto antagonista del receptor pd-1 y un agente potenciador; metodo para aumentar una respuesta de celulas t en un mamifero y su uso para tratar cancer.
AR061772A1 (es) Composicion de alto contenido de ion fluoruro para el cuidado oral y metodo para mantener la actividad anticaries
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
NI201500118A (es) Imidazopiridazinas sustituidas
CL2012000737A1 (es) Composición para entregar un agente activo que comprende una matriz de carbohidrato, un agente activo volátil atrapado adentro de la matriz de carbohidrato y un agente de expulsión atrapado dentro de la matriz de carbohidrato; sustrato seco para entregar un agente activo que comprende un sustrato y dicha composición de entrega.
CL2016000788A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.